Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 10:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Aripiprazole Clear all
Recruiting No phase listed Observational

Maternal And Infant Antipsychotic Study

NCT06049953
View directory record Official record
Conditions
Antipsychotics, Pregnancy
Interventions
Antipsychotics, Non-antipsychotic medication, No Medication
Drug · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 3 Interventional

Study of Aripiprazole in Patients With Acute Bipolar Mania

NCT00097266
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Placebo, Aripiprazole, Haloperidol
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
15
States / cities
Anaheim, California • Cerritos, California • Garden Grove, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 3 Interventional

Broad Effectiveness: Study With Aripiprazole

NCT00036361
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Wallingford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia

NCT01469039
View directory record Official record
Conditions
Schizophrenia
Interventions
ALKS 9072, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
26
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Results available

12- Week Open Label Treatment of Refractory Bipolar Depression

NCT00223496
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients

NCT01567527
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Intramuscular (IM) Depot Aripiprazole, Intramuscular (IM) Depot Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
42
States / cities
Birmingham, Alabama • Springdale, Arkansas • Beverly Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 1 Interventional

A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder

NCT02636842
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Aripiprazole Lauroxil
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Cerritos, California • Lemon Grove, California • Oakland, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Cariprazine in Patients With Schizophrenia

NCT01104766
View directory record Official record
Conditions
Schizophrenia
Interventions
Cariprazine, Aripiprazole, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Escondido, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 4 Interventional

Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia

NCT00080327
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Wallingford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 2Phase 3 Interventional

Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders

NCT00036127
View directory record Official record
Conditions
Schizophrenia
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
16
States / cities
Anaheim, California • Cerritos, California • Chula Vista, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills

NCT00223418
View directory record Official record
Conditions
Schizophenia Disorder, Schizoaffective Disorder
Interventions
aripiprazole
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 52 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2013 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

NCT01418339
View directory record Official record
Conditions
Tourette's Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
7 Years to 17 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
20
States / cities
Little Rock, Arkansas • Sacramento, California • Santa Ana, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 1 Interventional Results available

A Study of Safety and Tolerability in Subjects With Schizophrenia

NCT01354353
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, Aripiprazole
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Garden Grove, California • Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder

NCT00667745
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Optimized Treatment (OPT)
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 80 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Stanford, California • Boston, Massachusetts • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism

NCT00198107
View directory record Official record
Conditions
Autistic Disorder
Interventions
Aripiprazole, Placebo, D-cycloserine
Drug
Lead sponsor
Indiana University
Other
Eligibility
5 Years to 17 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa

NCT00685334
View directory record Official record
Conditions
Eating Disorders
Interventions
Olanzapine, Aripiprazole
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
16 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Aripiprazole on Cocaine Craving and Self-Administration

NCT00373880
View directory record Official record
Conditions
Cocaine Abuse
Interventions
Aripiprazole + Cocaine, Placebo + Cocaine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

NCT00423878
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone, Olanzapine, Quetiapine, Aripiprazole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Colton, California • Palo Alto, California • New Haven, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 3 Interventional

Aripiprazole Oral Acceptability Trial

NCT00101569
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
7
States / cities
Anaheim, California • National City, California • North Miami Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia

NCT01129882
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
52
States / cities
Bellevue, California • Garden Grove, California • Glendale, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2020 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Aripiprazole (Abilify) in Children With Symptoms of Mania

NCT00194077
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
4 Years to 9 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole

NCT04903353
View directory record Official record
Conditions
Weight Gain, Autism Spectrum Disorder, Medication Side Effect
Interventions
Comparison of Risperidone and Aripiprazole
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

NCT01416441
View directory record Official record
Conditions
Tourette's Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
7 Years to 18 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
36
States / cities
Dothan, Alabama • Little Rock, Arkansas • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 17, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Results available

Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)

NCT00892047
View directory record Official record
Conditions
Depression
Interventions
venlafaxine XR plus aripiprazole, venlafaxine plus placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Sep 17, 2026, 10:25 AM EDT